Answers are grounded in this paper and cite their sources.
Background and Objective: This study aimed to investigate the mechanisms through which epigallocatechin gallate (EGCG), a green tea polyphenol, enhances the antitumor activity of cisplatin (diamminedichloroplatinum, DDP) in breast cancer cells in vitro. Methods: Cytotoxicity assays and Western blotting were used to evaluate the effects of EGCG on DDP-mediated anticancer activity. Ferroptosis was assessed in MDA-MB-231 cells treated with DDP in the presence or absence of ferroptosis inhibitors using lipid peroxidation assays and Western blotting. Results: EGCG significantly sensitized MDA-MB-231 cells to cisplatin-induced cytotoxicity. Moreover, EGCG augmented cisplatin-induced increases in reactive oxygen species and lipid peroxides, elevated malondialdehyde content, and reduced glutathione levels. Western blot analysis revealed that EGCG promoted cisplatin-mediated upregulation of 4-HNE and downregulation of the anti-ferroptotic proteins SLC7A11 and GPX4. The ferroptosis inhibitor deferoxamine reversed EGCG/DDP-induced ferroptosis. Conclusions: EGCG enhances the efficacy of DDP by downregulating SLC7A11 and inducing ferroptosis at the cellular level. To our knowledge, this is the first study to clarify the synergistic mechanism between EGCG and DDP; thus, this work presents new pharmacological targets for the antitumor application of EGCG.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: